Nona Biosciences has entered a partnership with biopharmaceutical company Evive Biotech to expedite antibody discovery and drug development activities.
The companies will leverage Nona’s Harbour Mice antibody technology platform to discover antibodies.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Harbour Mice uses transgenic mice to create fully human monoclonal antibodies in a standard two-heavy and two-light chain (H2L2) setup and a heavy chain only (HCAb) format.
Nona Biosciences chairman Jingsong Wang stated: “Nona Biosciences is committed to bringing antibody discovery and research solutions to our partners better and faster.
“With the capabilities of Harbour Mice, we look forward to empowering our partners in antibody drug discovery and development, and helping more patients benefit from cutting-edge technologies and therapies.”
The company offers a comprehensive solution “from idea to IND [investigational new drug]”, encompassing validation of a target, as well as discovery of antibodies via preclinical studies.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataActivities offered by the company include readying antigens, immunisation in animals, screening of antibodies, antibody lead creation and engineering, evaluation of developability and pharmacology.
Nona uses Harbour Mice along with a group of specialists in the discovery of therapeutic antibodies.
Evive Biotech CEO and CMO Simon Li stated: “There is tremendous potential in antibody-based therapy, and I am very excited about this collaboration.
“Evive Biotech’s mission is to develop innovative biologic therapies for patients worldwide. We eagerly anticipate collaborating with Nona Biosciences to accelerate the discovery of innovative antibody therapies to benefit patients across the globe.”
Last month, Evive and Acrotech Biopharma received approval from the US Food and Drug Administration for Ryzneuta (efbemalenograstim alfa) to treat chemotherapy-induced febrile neutropenia in adults with non-myeloid malignancies who are receiving myelosuppressive anti-cancer therapies.
